Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05466708
Other study ID # 2021120884Esketamine
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date August 11, 2022
Est. completion date December 1, 2024

Study information

Verified date May 2024
Source The First Affiliated Hospital with Nanjing Medical University
Contact Zuo Xiangrong
Phone +86 13913979197
Email zuoxiangrong@njmu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A prospective, randomized controlled study was conducted to compare the effects of esketamine combined with dexmedetomidine in the sedation and analgesia treatment of mechanically ventilated patients in the ICU on the time to awaken, time to extubation, time to mechanical ventilation, time in the ICU, and on delirium.


Description:

Dexmedetomidine is a highly selective α2-adrenoceptor agonist with rapid onset of action, easy to wake up, no accumulation in the body, little inhibition of respiration, sedative, hypnotic and anxiolytic effects, and also has a certain analgesic effect.Clinical studies have shown that the use of dexmedetomidine for sedation in ICU patients is beneficial in reducing the duration of mechanical ventilation and the incidence of delirium is low, but the sedative effect of dexmedetomidine is relatively weak, and has the side effects of slowing down heart rate and lowering blood pressure, so its clinical application is limited.Esketamine is an isomer of ketamine, its effect is stronger than ketamine, and glutamate N-methyl D-aspartate (NMDA) receptor binding, play a sedative, hypnotic, analgesic effect, rapid onset, strong effect, and small respiratory inhibition, bronchodilator effect, the disadvantage is that there is a vasoconstrictor effect can cause increased blood pressure, increased heart rate. The combination of esketamine and dexmedetomidine can provide effective sedation and analgesia with the advantages of maintaining hemodynamic stability, maintaining stable spontaneous breathing and reducing psychiatric symptoms, and has been successfully used in clinical operations such as endoscopy, pediatric anesthesia and outpatient tooth extraction. The effectiveness and safety of esketamine in combination with dexmedetomidine for the sedation of mechanically ventilated patients in the ICU has not been evaluated. In this study, a prospective, randomized, controlled, single-center study was conducted to evaluate the efficacy and safety of esketamine in combination with dexmedetomidine for the sedation of mechanically ventilated patients in the ICU.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date December 1, 2024
Est. primary completion date December 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Mechanically ventilated with oral endotracheal intubation in the ICU; - Patients aged >18 years and <70 years; - Patients with expected mechanical ventilation time >24 hours. Exclusion Criteria: - Known or suspected allergy to esketamine, dexmedetomidine, remifentanil, or propofol; - Pregnancy or lactation periods; - Obesity defined as Body Mass Index >35kg/m2; - Extreme hemodynamic or respiratory instability due to severe burn or trauma (defined as Injury Severity Score =25); - Heavy drinking defined by WHO as drinking at least 60g of pure alcohol every day for men and at least 40g for women; - Terminally ill patients near death, such as patients with extensively metastatic tumor or refractory shock; - Long-term exposure to sedatives, opioid analgesics or antianxiety drugs; - Severe central nervous system disease such as cerebrovascular accidents, status epilepsy, or coma; - Acute or chronic severe liver disease (Child-Pugh class C or history of liver transplant); - Acute or chronic renal insufficiency needing dialysis; - Patients or authorized surrogates refuse to provide informed consents; - Mechanically ventilated for more than 24 hours prior to enrollment (not including the time on ventilators in the operation room).

Study Design


Intervention

Drug:
Esketamine combined with dexmedetomidine
Esketamine, injection, 50mg/ bottle, source: hospital pharmacy, production unit: Jiangsu Hengrui Pharmaceutical Co., LTD., validity: 2 years, storage condition: airtight shading, room temperature. Dexmedetomidine, injection, 0.2mg/ bottle, source: Hospital Pharmacy, manufacturer: Jiangsu Hengrui Pharmaceutical Co., LTD., expiration date: 18 months, storage condition: airtight shading, room temperature.
Dexmedetomidine
Dexmedetomidine, injection, 0.2mg/ bottle, source: Hospital Pharmacy, manufacturer: Jiangsu Hengrui Pharmaceutical Co., LTD., expiration date: 18 months, storage condition: airtight shading, room temperature.

Locations

Country Name City State
China The First Affiliated Hospital with Nanjing Medical University Nanjing Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
The First Affiliated Hospital with Nanjing Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Duration of mechanical ventilation Duration of mechanical ventilation after endotracheal intubation Usually within 14 days
Secondary Time to extubation Daily offline screening, SBT test if eligible, and extubation if SBT is successful Usually within 14 days
Secondary Duration of ICU stay Length of stay in ICU Usually within 28 days
Secondary 28-day mortality rate Mortality of patients within 28 days from the time of tracheal intubation Within 28 days
Secondary Recovery time From the stop of sedatives to awakening Within 14 days
Secondary Dose of Propofol Total dose of rescue propofol Within 14 days
Secondary Occurrence of delirium The proportion of participants who have at least one positive CAM-ICU Within 14 days
Secondary Adverse reactions Adverse reactions that patients experience with the medication, such as hypertension, hypotension, rapid heart rate, slow heart rate Within 28 days
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05534230 - Dexmedetomidine for Pain Reduction in CABG N/A
Recruiting NCT06275698 - HONEY for the Treatment of POst-Tonsillectomy Pain N/A
Recruiting NCT04436224 - Hydromorphone for ICU-analgesia in Patients With Non-mechanical Ventilation Phase 4
Not yet recruiting NCT04548323 - Hypoalgesic Effects of Walking and Running Imagined
Completed NCT06054945 - Clinical Impact of IPACK Block Addition to Suprainguinal Fascia Iliaca Block
Completed NCT04394481 - Extension of Analgesia by Combined Injection of Dexamethasone and Dexmedetomidine After Arthroscopic Shoulder Surgery Phase 4
Completed NCT04690647 - The Efficacy of Suprainguinal Fascia Iliaca Compartment Block for Analgesia After Elective Total Hip Replacement. N/A
Completed NCT05034601 - ESPB vs TPVB for Postoperative Analgesia After the Nuss Procedure N/A
Completed NCT03740815 - Feasibility of Serratus Plane Block Associated With Sedation in Axillary Dissection N/A
Recruiting NCT05454202 - Assessment of the Interest of ANI in the Non-communicating Patient in Palliative Care
Recruiting NCT04554186 - Serratus Anterior Plane Block Versus Thoracic Paravertebral Block. N/A
Suspended NCT04860635 - Safety of F14 Following Total Knee Replacement Phase 2/Phase 3
Not yet recruiting NCT06393777 - Effectiveness of Pre-administered Natural Sweet-tasting Solution (Honey) for Decreasing Pain of Needle Insertion N/A
Not yet recruiting NCT04519463 - The Effect of Local Anesthesia With Lidocaine During Insertion and Removal of Nasal Packing Early Phase 1
Completed NCT02916342 - Interscalene Block Versus Combined Supraprascapular: Axillary Nerve Blocks Phase 4
Completed NCT03206554 - Local Infiltration Analgesia in Total Knee Arthroplasty Phase 2
Not yet recruiting NCT02549118 - Tenoxicam for Intrapartum Analgesia Phase 2
Not yet recruiting NCT02190760 - Comparison Between Perineural and Systemic Effect of Dexamethasone for Interscalene Brachial Plexus Block. N/A
Completed NCT01789606 - Self-Selection and Actual Use Trial of Ibuprofen 600 mg Immediate Release/Extended Caplet Phase 3
Completed NCT01299584 - ULTIVA Post Marketing Surveillance N/A